Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. - Wikidata - wikimedia - TriplyDB

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

http://www.wikidata.org/entity/Q33585882

about

Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010 Increasing Disadvantages in Cancer Survival in New Zealand Compared to Australia, between 2000-05 and 2006-10 Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.

P2860

Q35236068-BDE8790B-BCC3-44BB-9C0C-778F88FCD017 Q35944238-AE1D846B-852A-46C3-8FDD-6DD75F7D52F9 Q43706654-77FF9867-EC8B-44F2-838F-84ED8818F43C

P2860

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

http://www.wikidata.org/entity/Q33585882

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@ast

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@en

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@nl

type

label

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@ast

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@en

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@nl

prefLabel

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@ast

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@en

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@nl

P1433

Q33585882-7C3CA5B4-09E3-47FF-A048-E28DDC2D7CB7

P1476

Q33585882-874D244C-EA8E-48E4-BE2E-C12F3E9AE594

P2093

Q33585882-3026C8DF-AB77-4828-8CAE-1BE0E996CBDB

Q33585882-A0090DAC-3508-4F52-BCB5-D5DF3EBD63CC

Q33585882-BC283682-7977-469F-86AF-FD91A14F1FDC

P2860

Q33585882-07F410E2-099C-4827-ADC3-8D9CE83E0838

Q33585882-0D159A8E-D56B-4F56-8332-59F15ED24C07

Q33585882-1D5076D7-B102-4510-9398-E4F76F59ACE0

Q33585882-254E3FA1-ECE2-4C4E-A6FF-4780E2EA95C0

Q33585882-2B4C5F1E-E911-4D97-B2D2-08F8075D7FFF

Q33585882-2BE5879F-66E9-428C-8E22-64833073BE2A

Q33585882-31F1E0D0-0E22-4867-9B7F-30F3AFB800E5

Q33585882-3D090B47-25DA-4C35-93D9-31219E2B81EE

Q33585882-498413EC-3C67-4C65-AEF1-E0EC397B8788

Q33585882-4C345C51-C3E4-4B06-BCBF-943AB63F202C

P2888

Q33585882-92EFD2F7-A38E-492F-90ED-ABB6299C4206

P304

Q33585882-F86BCA7D-B960-41E3-A751-DBD713F3DDEE

P31

Q33585882-53790A1C-C1B3-421B-A852-0D836D7075D0

P356

Q33585882-459A5DE0-63FD-4633-8E23-FDC95C438441

P407

Q33585882-0833C3F4-D16E-40B9-BDE7-E5ED253FB065

P478

Q33585882-69CE792B-6AAE-4B78-96DB-5B7DCC041349

P577

Q33585882-F944E321-6D39-4BD8-84D2-D3C55C4B935F

P5875

Q33585882-9F253275-F17B-42A4-B72B-373AACE30AC3

P6179

Q33585882-93601991-2AAD-4490-864D-6DCF1F3EFCDE

P698

Q33585882-C1E66383-16EC-4FB8-8786-0AA4A03EE5F9

P921

Q33585882-5CCD51D9-4F9B-4C99-8094-2EF53749B160

P932

Q33585882-3E21C1A8-7A0E-4101-A1BF-B480E18A0508

P356

1471-2407-10-231

P1433

P1476

Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia.

@en

P2093

Dianne L O'Connell

http://www.w3.org/2001/XMLSchema#string

Wendy H Chen

http://www.w3.org/2001/XMLSchema#string

Xue Q Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Expert Review of Non-Hodgkin's Lymphomas in a Population-Based Cancer Registry: Reliability of Diagnosis and Subtype Classifications

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

Interpreting trends in cancer patient survival.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s.

Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study.

P2888

1471-2407-10-231

P304

231

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-10-231

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44625651

http://www.w3.org/2001/XMLSchema#string

P6179

1048368779

http://www.w3.org/2001/XMLSchema#string

P698

20497580

http://www.w3.org/2001/XMLSchema#string

P921

P932

2886045

http://www.w3.org/2001/XMLSchema#string